HB 1471 2012

A bill to be entitled

An act relating to prescription drugs; amending s. 499.033, F.S.; requiring products containing ephedrine or a related compound to be dispensed by prescription only; providing a definition; providing rulemaking authority; repealing s. 893.1495, F.S., relating to the retail sale of ephedrine and related compounds; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. Section 499.033, Florida Statutes, is amended to read:

499.033 Ephedrine <u>and related compounds</u>; prescription required.—<u>Ephedrine is declared to be a prescription drug</u>.

(1) Except as provided in subsection (2), Any product that contains any quantity of ephedrine or a related compound, a salt of ephedrine, an optical isomer of ephedrine, or a salt of an optical isomer of ephedrine may be dispensed only upon the prescription of a duly licensed practitioner authorized by the laws of the state to prescribe prescription drugs. As used in this section, the term "ephedrine or a related compound" means ephedrine, pseudoephedrine, phenylpropanolamine, or any of their salts, optical isomers, or salts of optical isomers.

(2) A product containing ephedrine described in paragraphs
(a)-(e) is exempt from subsection (1) if it may lawfully be sold
over the counter without a prescription under the federal act;
is labeled and marketed in a manner consistent with the

Page 1 of 3

HB 1471 2012

29

30

31

32

33

34

35

36

37

38

39

40

41 42

43

44

45

46

47

48 49

50

51

52

53

54

55

56

pertinent United States Food and Drug Administration Over-the-Counter Tentative Final or Final Monograph; and is manufactured and distributed for legitimate medicinal use in a manner that reduces or eliminates the likelihood of abuse, when considered in the context with: the package sizes and the manner of packaging of the drug product; the name and labeling of the product; the manner of distribution, advertising, and promotion of the product; the duration, scope, health significance, and societal cost of abuse of the particular product; the need to provide medically important ephedrine-containing therapies to the public for United States Food and Drug Administration approved indications on an unrestricted, over-the-counter basis; and other facts as may be relevant to and consistent with public health and safety. (a) Solid oral dosage forms that combine active ingredients in the following ranges for each dosage unit: 1. Theophylline (100-130mg), ephedrine (12.5-24mg). 2. Theophylline (60-100mg), ephedrine (12.5-24mg), quaifenesin (200-400mg). 3. Ephedrine (12.5-25mg), quaifenesin (200-400mg). 4. Phenobarbital (not greater than 8mg) in combination with the ingredients of subparagraph 1. or subparagraph 2. (b) Liquid oral dosage forms that combine active ingredients in the following ranges for each (5ml) dose: 1. Theophylline (not greater than 45mg), ephedrine (not greater than 36mg), quaifenesin (not greater than 100mg), phenobarbital (not greater than 12mg). Phenylephrine (not greater than 5mg), ephedrine (not

Page 2 of 3

HB 1471 2012

greater than 5mg), chlorpheniramine (not greater than 2mg),

dextromethorphan (not greater than 10mg), ammonium chloride (not
greater than 40mg), ipecac fluid extract (not greater than
0.005ml).
(c) Anorectal preparations containing less than 5 percent
ephedrine.
(d) Nasal decongestant compounds, mixtures, or
preparations containing 0.5 percent or less ephedrine.
(e) Any drug product containing ephedrine that is marketed

(e) Any drug product containing ephedrine that is marketed pursuant to an approved new drug application or legal equivalent under the federal act.

(2) (3) The department may implement this section by rule. Section 2. Section 893.1495, Florida Statutes, is repealed.

Section 3. This act shall take effect July 1, 2012.